Video

Dr. You on Findings from the TROPHIMMUN Study in Gestational Trophoblastic Tumors

Benoit You, MD, PhD, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab.

Benoit You, MD, PhD, academic staff physician in the Medical Oncology Department of Lyon University Hospital, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab (Bavencio).

Investigators enrolled a total of 15 patients and out of those, 8 experienced hCG normalization, says You. They found that patients could stop avelumab and none presented with any relapse with 25 months of follow-up, and within 29 months, patients had successful treatment with avelumab. One patient who was successfully treated with avelumab was able to develop a normal pregnancy 1 year after the discontinuation of avelumab and normalization of hCG; this was the first report of a normal pregnancy after successful treatment with immunotherapy, says You. The 7 remaining patients who were resistant to avelumab were successfully treated with chemotherapy with or without surgery, concludes You.

Related Videos
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Manali Kamdar, MD
Ibrahim Aldoss, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ana Christina Garrido-Castro, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Jean-Marc Classe, MD, PhD, Nantes Université